Search results for "MESH: Prognosis"

showing 10 items of 11 documents

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melti…

2016

Background Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation markers do not translate into clinical applications is lack of independent validation of methylation markers, often caused by differences in methylation analysis techniques. We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series. Methods In the current study, we analy…

Male0301 basic medicineMESH: Sequence Analysis DNABisulfite sequencingAnalytic sensitivityMS-HRMMESH : AgedMESH : Promoter Regions GeneticPolymerase Chain Reaction[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH: DNA MethylationMESH : FemaleMESH : Proto-Oncogene Proteins c-retPromoter Regions GeneticMESH: CpG IslandsMESH : Polymerase Chain ReactionGenetics (clinical)MESH: AgedDNA methylationMESH : PrognosisMethylationMESH : CpG IslandsPrognosispyrosequencing030220 oncology & carcinogenesisMESH: Survival AnalysisDNA methylationFemaleMESH : Colorectal NeoplasmsMESH : Sensitivity and SpecificityColorectal NeoplasmsMESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerBiologySensitivity and SpecificityMESH: Proto-Oncogene Proteins c-retHigh Resolution MeltMESH: Prognosis03 medical and health sciencesMESH: Promoter Regions GeneticGeneticsHumansMolecular BiologyAgedMESH: HumansResearchMSPProto-Oncogene Proteins c-retMESH : HumansMESH: Polymerase Chain ReactionSequence Analysis DNASurvival AnalysisMolecular biologyMESH: Sensitivity and SpecificityMESH: Male030104 developmental biologyPyrosequencingIllumina Methylation AssayCpG IslandsCancer biomarkersClinical sensitivityPrimer (molecular biology)MESH : Survival AnalysisRETMESH: FemaleMESH : DNA MethylationMESH: Colorectal NeoplasmsDevelopmental BiologyMESH : Sequence Analysis DNA
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct

Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study.

2016

IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 p…

MaleEpidemiologyMESH : Aged[ SDV.CAN ] Life Sciences [q-bio]/CancerMESH: Anus NeoplasmsMESH: Research Papers: Gastrointestinal Cancer0302 clinical medicineMESH : ChildMESH: ChildMedicineMESH: IncidenceMESH : Carcinoma Squamous CellChildeducation.field_of_studyMESH: Middle AgedObstetricsMESH : InfantMESH: Carcinoma Squamous CellMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisResearch PapersMESH: InfantMESH : Incidence3. Good healthSurvival RateOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisCarcinoma Squamous Cell030211 gastroenterology & hepatologymedicine.medical_specialtyMESH : Research Papers: Gastrointestinal CancerMitomycinMESH : Young AdultUnited-StatesMESH: Prognosis03 medical and health sciencesMESH : AdolescentHumansAnal cancerMESH : Middle AgedMESH : Anus NeoplasmseducationAgedGynecologyMESH: AdolescentMESH: HumansMESH : HumansMESH: Child PreschoolPublic Health Environmental and Occupational HealthInfantMESH : Follow-Up StudiesMESH: AdultEpidermoid Carcinomamedicine.diseaseCervical-cancerincidenceRandomized-trialMESH: FemaleCancer ResearchMESH: RegistriesMESH : Child PreschoolRisk FactorsMESH: Risk FactorsMESH : FemaleRegistriesCervical cancerMESH: AgedMESH : PrognosisIncidence (epidemiology)SmokingMESH: Infant NewbornMESH : AdultMiddle AgedMESH : Survival RateMESH : Risk Factorsmedicine.anatomical_structureFemaleFranceAdultHuman-PapillomavirusRiskAdolescentMESH: Survival Rateanal cancerMESH : MalePopulationHuman Papilloma Virus Vaccine[SDV.CAN]Life Sciences [q-bio]/CancerCancer IncidenceMESH : Infant NewbornsurvivalYoung Adultcancer registryMESH : FranceSurvival rateRadiotherapybusiness.industryInfant NewbornCancerMESH: MaleMESH: FrancebusinessMESH : RegistriesFollow-Up Studies
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

2014

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated wi…

MaleMESH: Combined Modality TherapyAnal Carcinomamedicine.medical_treatmentMESH: Lymphatic MetastasisMedical OncologyMESH: Anus Neoplasms0302 clinical medicineDiagnosisSocieties MedicalMESH: Medical Oncologyeducation.field_of_studyIncidence (epidemiology)Follow-upAnal MarginMESH: Carcinoma Squamous CellGeneral MedicineHematologyMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisCombined Modality Therapy3. Good healthmedicine.anatomical_structureOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleRadiologymedicine.medical_specialtyHealth Planning GuidelinesPopulationMESH: Societies MedicalRectumGuidelinesMESH: Prognosis03 medical and health sciencesmedicineAnal cancerHumansRadiology Nuclear Medicine and imagingeducationNeoplasm StagingMESH: Humansbusiness.industryCancerAnusmedicine.diseaseMESH: MaleSurgeryRadiation therapyTreatmentSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieAnal cancerbusinessMESH: FemaleFollow-Up Studies
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct